BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis

Qi Wang; Wei-guo Hu; Qi-bin Song; Jia Wei

Your Location：

Home >

Browse articles >

BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis

中国医学科学杂志（英文版） 2014年第4期页码：197-203

• 论著 • | Updated：2024-04-10

- BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis
- Affiliations：
  
  Department of Oncology, Renmin Hospital of Wuhan University,Wuhan,China,430060
- Author bio：
- Funds：
- DOI：
  中图分类号：
- 网络出版日期：2014-11-28，
  
  纸质出版日期：2014
- Accepted：
Scan QR Code
Qi Wang, Wei-guo Hu, Qi-bin Song, 等. BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis[J]. 中国医学科学杂志（英文版）, 2014,(4):197-203.

Qi Wang, Wei-guo Hu, Qi-bin Song, et al. BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis[J]. Chinese medical sciences journal, 2014, (4): 197-203.
Qi Wang, Wei-guo Hu, Qi-bin Song, 等. BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis[J]. 中国医学科学杂志（英文版）, 2014,(4):197-203. DOI：

Qi Wang, Wei-guo Hu, Qi-bin Song, et al. BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis[J]. Chinese medical sciences journal, 2014, (4): 197-203. DOI：

摘要

Objective To investigate the correlation between BRAF V600E mutation and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) therapeutic effects in metastatic colorectal cancer. Methods Studies were included into meta-analysis to investigate the association between BRAF V600E mutation and clinical outcome in metastatic colorectal cancer patients treated with anti-EGFR MoAbs. Results A total of 7 studies were included in this meta-analysis. The 7 studies included 1352 patients in total

sample sizes ranged from 67 to 493. Objective response rate (ORR)

progression-free survival (PFS) and overall survival (OS) were collected from included studies and were used to assess the strength of the relation. In patients with wild-type KRAS

the pooled odds ratio for ORR of mutant BRAF over wild-type BRAF was 0.27 (95% CI=0.10-0.70). BRAF mutation predicted a deterioration in PFS and OS in wild-type KRAS patients treated with anti-EGFR MoAbs (hazard ratio=2.78

95% CI=1.62-4.76; hazard ratio=2.54

95% CI=1.93-3.32). Conclusion BRAF V600E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR MoAbs.

Abstract

sample sizes ranged from 67 to 493. Objective response rate (ORR)

progression-free survival (PFS) and overall survival (OS) were collected from included studies and were used to assess the strength of the relation. In patients with wild-type KRAS

95% CI=1.62-4.76; hazard ratio=2.54

95% CI=1.93-3.32). Conclusion BRAF V600E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR MoAbs.

关键词

Keywords

references

浏览量

2020

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

USING OF MULTISLICE HELICAL CT COLONOGRAPHY IN PATIENTS WITH MALIGNANT LESIONS OF COLON

Chinese Herbal Medicine in Treatment of Polyhydramnios:a Meta-analysis and Systematic Review^025B3;

Effect of Timing of Tracheotomy on Clinical Outcomes: an Update Meta-analysis Including 11 Trials

Therapeutic Effect and Safety of Ustekinumab for Plaque Psoriasis: A Meta-analysis

Probiotics’ Preventive Effect on Pediatric Food Allergy: A Meta-analysis of Randomized Controlled Trials